<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00386763</url>
  </required_header>
  <id_info>
    <org_study_id>CCOA566B2303</org_study_id>
    <nct_id>NCT00386763</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.</brief_title>
  <official_title>A Randomized, Investigator-Blinded, Multicenter, Parallel-Group Study to Compare Efficacy, Safety and Tolerability of Arthemeter/ Lumefantrine Dispersible Tablet Formulation vs. Artemether/ Lumefantrine 6-Dose Crushed Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants and Children.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of artemether-lumefantrine against
      uncomplicated malaria caused P. falciparum in children of 5-35 kg bodyweight.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date>March 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients free of parasites at day 28.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients free of parasites at 7 days and at 14 days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clearance from parasites</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clearance of fever</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology and biochemistry parameters</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
  </secondary_outcome>
  <enrollment>890</enrollment>
  <condition>Malaria</condition>
  <condition>Falciparum</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female infants and children ≤12 years of age

          -  body weight of ≥5 kg and &lt;35 kg,

          -  with a confirmed diagnosis of uncomplicated malaria caused by the P. falciparum
             parasite

        Exclusion Criteria:

          -  complicated malaria

          -  persistent vomiting

          -  malaria due to parasites other than P. falciparum

          -  antimalarial treatment received in the past 2 weeks

          -  known chronic disease e.g. positive HIV status, severe cardiac, renal, or hepatic
             disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Benin</city>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Kenya</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Mali</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Mozambique</city>
        <country>Mozambique</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Tanzania</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Benin</country>
    <country>Kenya</country>
    <country>Mali</country>
    <country>Mozambique</country>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2006</study_first_submitted>
  <study_first_submitted_qc>October 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2006</study_first_posted>
  <last_update_submitted>March 11, 2009</last_update_submitted>
  <last_update_submitted_qc>March 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Novartis</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Marsh fever</keyword>
  <keyword>Plasmodium infections</keyword>
  <keyword>Remittent fever</keyword>
  <keyword>Paludism</keyword>
  <keyword>Artemether</keyword>
  <keyword>Artemisinins</keyword>
  <keyword>Malaria</keyword>
  <keyword>Benflumetol</keyword>
  <keyword>Lumefantrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

